

## PRODUCT INFORMATION

|   |   |
|---|---|
| <b>Common Name</b>                      | Bimzelx;CDP-4940;CDP4940;UCB-4940;UCB4940   |
| <b>Synonyms</b>                         | IL17;CTLA8;IL-17;ILA17;CTLA-8;IL-17A  |
| <b>Applications</b>                     | Flow Cyt  |
| <b>Recommended Dilutions</b>            | Flow Cyt 1:100  |
| <b>Formulation &amp; Reconstitution</b> | Liquid□PBS with 0.05% Proclin300, 1% BSA  |
| <b>Host Species</b>                     | Whole mAb   |
| <b>IgG type</b>                         | IgG1  |
| <b>Reactivity</b>                       | Human   |
| <b>Target</b>                           | IL17A   |
| <b>Uniprot ID</b>                       | Q16552  |
| <b>Description</b>                      | PE-conjugated Anti-IL17A(bimekizumab biosimilar) mAb  |
| <b>Delivery</b>                         | 6-8 weeks   |
| <b>Storage &amp; Shipping</b>           | Store at 2°C-8°C for 6 months   |
| <b>Background</b>                       | Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals. |
| <b>Usage</b>                            | Research use only   |
| <b>Conjugate</b>                        | PE-conjugated   |

DIMABIO CONFIDENTIAL

